Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | Director | August 25, 2026 | August 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date August 25, 2026 · Filed August 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,596 |
Ending reported balance
After 2026-08-25 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-08-25 · Exercise / conversion · Acquired 21,132 · Balance 52,728 Row 2 · 2026-08-25 · Exercise / conversion · Acquired 12,429 · Balance 65,157 Row 3 · 2026-08-25 · Sale · Disposed 33,561 · Balance 31,596 F1: This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 6, 2026. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $194.12 · Expires 2033-05-26 | Direct | 7,044 |
Reported balance
After 2026-08-25 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-08-25 · Exercise / conversion · Disposed 21,132 · Balance 7,044 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $208.44 · Expires 2034-05-31 | Direct | 12,429 |
Reported balance
After 2026-08-25 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-08-25 · Exercise / conversion · Disposed 12,429 · Balance 12,429 |
| Common StockSEC Table I · non-derivative | Indirect2024 GRAT | 5,423 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 5,423 |
| Common StockSEC Table I · non-derivative | Indirect2025 GRAT | 10,780 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 10,780 |
| Common StockSEC Table I · non-derivative | Indirect2026 GRAT | 20,000 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 20,000 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 155,611 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 155,611 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust Held By Spouse | 10,000 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 10,000 |
Filing footnotes · ownership attribution and instrument terms
F1: This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 6, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 23, 2021 Filed Feb 24, 2021 16:10 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,249 | $278.07 | $347,309.80 |
DisclosureSEC source: 0001127602-21-007525 · form4.xml · nonDerivative · entry 14 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,835 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F10 · price: This transaction was executed in multiple trades at prices ranging from $277.5 to $278.43 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 23, 2021 Filed Feb 24, 2021 16:10 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,809 | $277.00 | $501,094.63 |
DisclosureSEC source: 0001127602-21-007525 · form4.xml · nonDerivative · entry 13 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,084 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F9 · price: This transaction was executed in multiple trades at prices ranging from $276.605 to $277.405. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 23, 2021 Filed Feb 24, 2021 16:10 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,309 | $276.03 | $361,322.62 |
DisclosureSEC source: 0001127602-21-007525 · form4.xml · nonDerivative · entry 12 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,893 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $275.535 to $276.45. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 23, 2021 Filed Feb 24, 2021 16:10 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 454 | $274.81 | $124,762.06 |
DisclosureSEC source: 0001127602-21-007525 · form4.xml · nonDerivative · entry 11 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,202 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $274.48 to $275.455. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 23, 2021 Filed Feb 24, 2021 16:10 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 20,295 | $109.34 | $2,219,055.30 |
DisclosureSEC source: 0001127602-21-007525 · form4.xml · nonDerivative · entry 10 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2021 Filed Feb 24, 2021 16:10 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 1,994 | $283.59 | $565,478.46 |
DisclosureSEC source: 0001127602-21-007525 · form4.xml · nonDerivative · entry 9 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,361 Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 16:10 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 17,436 | $0.00 Strike: $144.67 | $0.00 |
DisclosureSEC source: 0001127602-21-007525 · form4.xml · derivative · entry 26 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,872 Underlying: Common Stock · 17,436 shares Expires 2024-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 16:10 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 1,814 | $289.55 | $525,243.70 |
DisclosureSEC source: 0001127602-21-007525 · form4.xml · nonDerivative · entry 8 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,355 Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 16:10 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 52 | $285.79 | $14,861.08 |
DisclosureSEC source: 0001127602-21-007525 · form4.xml · nonDerivative · entry 7 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,169 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 16:10 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 4,240 | $284.50 | $1,206,283.39 |
DisclosureSEC source: 0001127602-21-007525 · form4.xml · nonDerivative · entry 6 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,221 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $284.09 to $284.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 16:10 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 4,020 | $283.56 | $1,139,910.80 |
DisclosureSEC source: 0001127602-21-007525 · form4.xml · nonDerivative · entry 5 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,461 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $283.09 to $284.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 16:10 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 5,476 | $282.49 | $1,546,928.93 |
DisclosureSEC source: 0001127602-21-007525 · form4.xml · nonDerivative · entry 4 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,481 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $282.08 to $283.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 16:10 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 2,223 | $281.69 | $626,189.53 |
DisclosureSEC source: 0001127602-21-007525 · form4.xml · nonDerivative · entry 3 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,957 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $281.31 to $282.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 16:10 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,425 | $280.66 | $399,944.06 |
DisclosureSEC source: 0001127602-21-007525 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,180 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $280.08 to $280.95. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 16:10 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 17,436 | $144.67 | $2,522,466.12 |
DisclosureSEC source: 0001127602-21-007525 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,605 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 16:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 31 | $289.16 | $8,963.96 |
DisclosureSEC source: 0001127602-21-005677 · form4.xml · nonDerivative · entry 9 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,169 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 16:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 2,402 | $287.99 | $691,752.94 |
DisclosureSEC source: 0001127602-21-005677 · form4.xml · nonDerivative · entry 8 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,200 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F9 · price: This transaction was executed in multiple trades at prices ranging from $287.76 to $288.62. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 16:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 4,775 | $287.18 | $1,371,289.28 |
DisclosureSEC source: 0001127602-21-005677 · form4.xml · nonDerivative · entry 7 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,602 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $286.76 to $287.71. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 16:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 2,490 | $286.48 | $713,343.17 |
DisclosureSEC source: 0001127602-21-005677 · form4.xml · nonDerivative · entry 6 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,377 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $285.765 to $286.74. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 16:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 9,643 | $285.15 | $2,749,722.66 |
DisclosureSEC source: 0001127602-21-005677 · form4.xml · nonDerivative · entry 5 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,867 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $284.80 to $285.70. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 16:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 4,038 | $284.21 | $1,147,633.52 |
DisclosureSEC source: 0001127602-21-005677 · form4.xml · nonDerivative · entry 4 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,510 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $283.84 to $284.7075. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 16:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 727 | $282.96 | $205,714.10 |
DisclosureSEC source: 0001127602-21-005677 · form4.xml · nonDerivative · entry 3 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,548 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $282.76 to $283.11. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 16:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 3,766 | $282.39 | $1,063,484.51 |
DisclosureSEC source: 0001127602-21-005677 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,275 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $281.91 to $282.69. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 16:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 2,128 | $281.32 | $598,652.36 |
DisclosureSEC source: 0001127602-21-005677 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,041 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $280.76 to $281.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 16:08 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 32,753 | $260.88 | $8,544,602.64 |
DisclosureSEC source: 0001127602-21-003425 · form4.xml · nonDerivative · entry 4 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,169 Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 16:08 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 75,129 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-003425 · form4.xml · nonDerivative · entry 3 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,922 F3 · shares: Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on February 23, 2018. Read SEC document |
| January 14, 2021 Filed Feb 2, 2021 16:08 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-003425 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,793 Read SEC document |
| November 13, 2020 Filed Feb 2, 2021 16:08 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 4,706 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-003425 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · 2018 GRAT Disclosed balance after: 0 F1 · shares: On 11/13/2020: 4,706 shares were gifted from the 2018 GRAT account to Mr. Foster's children. F2 · ownership.nature: On 11/05/2020: 5,987 shares were transferred from the 2019 GRAT account to Direct Holdings. On 11/13/2020: 8,094 shares were transferred from the 2018 GRAT account to Direct Holdings. Read SEC document |
| November 02, 2020 Filed Nov 3, 2020 21:05 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,018 | $234.31 | $238,523.10 |
DisclosureSEC source: 0001127602-20-027994 · form4.xml · nonDerivative · entry 6 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,777 F4 · price: This transaction was executed in multiple trades at prices ranging from $234.23 to $234.39. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 02, 2020 Filed Nov 3, 2020 21:05 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 5,206 | $233.74 | $1,216,850.44 |
DisclosureSEC source: 0001127602-20-027994 · form4.xml · nonDerivative · entry 5 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,795 F3 · price: This transaction was executed in multiple trades at prices ranging from $233.22 to $234.19. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 02, 2020 Filed Nov 3, 2020 21:05 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,191 | $232.56 | $276,977.05 |
DisclosureSEC source: 0001127602-20-027994 · form4.xml · nonDerivative · entry 4 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,001 F2 · price: This transaction was executed in multiple trades at prices ranging from $232.24 to $233.215. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 02, 2020 Filed Nov 3, 2020 21:05 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 14,585 | $231.74 | $3,379,916.23 |
DisclosureSEC source: 0001127602-20-027994 · form4.xml · nonDerivative · entry 3 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,192 F1 · price: This transaction was executed in multiple trades at prices ranging from $231.22 to $232.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 07, 2020 Filed Nov 3, 2020 21:05 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-027994 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,777 Read SEC document |
| October 06, 2020 Filed Nov 3, 2020 21:05 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-027994 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,777 Read SEC document |
| August 07, 2020 Filed Aug 10, 2020 20:25 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 19,287 | $217.77 | $4,200,160.85 |
DisclosureSEC source: 0001127602-20-023257 · form4.xml · nonDerivative · entry 4 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,777 F2 · price: This transaction was executed in multiple trades at prices ranging from $217.66 to $218.275. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 07, 2020 Filed Aug 10, 2020 20:25 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 4,713 | $216.34 | $1,019,610.42 |
DisclosureSEC source: 0001127602-20-023257 · form4.xml · nonDerivative · entry 3 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,064 F1 · price: This transaction was executed in multiple trades at prices ranging from $216.31 to $216.58. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 20:25 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 4,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-023257 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,777 Read SEC document |
| July 16, 2020 Filed Aug 10, 2020 20:25 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-023257 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,377 Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 18:18 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 38,310 | $0.00 Strike: $179.66 | $0.00 |
DisclosureSEC source: 0001127602-20-018390 · form4.xml · derivative · entry 9 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,310 Underlying: Common Stock · 38,310 shares Expires 2030-05-29 F2 · shares: Stock Options vest as follows: 9,577 on May 29, 2021, 9,578 on May 29, 2022, 9,577 on May 29, 2023 and 9,578 on May 29, 2024. Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 18:18 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 11,483 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-018390 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,377 F1 · shares: Unvested restricted stock units vest as follows: 2,870 on May 29, 2021, 2,871 on May 29, 2022, 2,871 on May 29, 2023 and 2,871 on May 29, 2024. Read SEC document |
| May 18, 2020 Filed May 19, 2020 20:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 17,435 | $175.00 | $3,051,125.00 |
DisclosureSEC source: 0001127602-20-017151 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,894 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| May 18, 2020 Filed Nov 17, 2020 21:32 UTC Amendment | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 17,435 | $0.00 Strike: $144.67 | $0.00 |
DisclosureSEC source: 0001127602-20-029256 · form4a.xml · derivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,308 Underlying: Common Stock · 17,435 shares Expires 2024-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transaction was inadvertently omitted from the Reporting Person's Form 4 filed on May 19, 2020 due to an administrative error. Read SEC document |
| May 18, 2020 Filed Nov 17, 2020 21:32 UTC Amendment | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 17,435 | $144.67 | $2,522,321.45 |
DisclosureSEC source: 0001127602-20-029256 · form4a.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transaction was inadvertently omitted from the Reporting Person's Form 4 filed on May 19, 2020 due to an administrative error. Read SEC document |
| May 14, 2020 Filed May 19, 2020 20:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-017151 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,329 Read SEC document |
| May 11, 2020 Filed May 13, 2020 15:02 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,565 | $164.43 | $257,331.54 |
DisclosureSEC source: 0001127602-20-016380 · form4.xml · nonDerivative · entry 5 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,329 F6 · price: This transaction was executed in multiple trades at prices ranging from $164.33 to $164.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: On 04/14/2020, the reporting person contributed 20,000 shares of CRL Common Stock to a grantor retained annuity trust for the benefit of himself and his two adult children. Read SEC document |
| May 11, 2020 Filed May 13, 2020 15:02 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 4,706 | $163.89 | $771,245.16 |
DisclosureSEC source: 0001127602-20-016380 · form4.xml · nonDerivative · entry 4 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,894 F5 · price: This transaction was executed in multiple trades at prices ranging from $163.34 to $164.32. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: On 04/14/2020, the reporting person contributed 20,000 shares of CRL Common Stock to a grantor retained annuity trust for the benefit of himself and his two adult children. Read SEC document |
| May 11, 2020 Filed May 13, 2020 15:02 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 2,025 | $162.73 | $329,528.45 |
DisclosureSEC source: 0001127602-20-016380 · form4.xml · nonDerivative · entry 3 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,600 F4 · price: This transaction was executed in multiple trades at prices ranging from $162.33 to $163.315. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: On 04/14/2020, the reporting person contributed 20,000 shares of CRL Common Stock to a grantor retained annuity trust for the benefit of himself and his two adult children. Read SEC document |
| May 11, 2020 Filed May 13, 2020 15:02 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 5,582 | $161.84 | $903,414.32 |
DisclosureSEC source: 0001127602-20-016380 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,625 F3 · price: This transaction was executed in multiple trades at prices ranging from $161.335 to $162.325. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: On 04/14/2020, the reporting person contributed 20,000 shares of CRL Common Stock to a grantor retained annuity trust for the benefit of himself and his two adult children. Read SEC document |
| May 11, 2020 Filed May 13, 2020 15:02 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 3,568 | $160.85 | $573,913.16 |
DisclosureSEC source: 0001127602-20-016380 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,207 F2 · price: This transaction was executed in multiple trades at prices ranging from $160.33 to $161.29. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: On 04/14/2020, the reporting person contributed 20,000 shares of CRL Common Stock to a grantor retained annuity trust for the benefit of himself and his two adult children. Read SEC document |
| February 26, 2020 Filed Feb 26, 2020 17:28 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 2,271 | $162.46 | $368,946.66 |
DisclosureSEC source: 0001127602-20-007869 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,775 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.